1.Recalcitrant gram-positive bacterial keratitis treated with intrastromal levofloxacin 1.5% ophthalmic solution: A case report and review of literature
Bobbie Marie M. Santos ; Josept Mari S. Poblete ; George Michael N. Sosuan ; Pablito F. Sandoval Jr. ; Billie Jean T. Cordero ; David Ammiel R. Tirol V ; Ruben Lim Bon Siong
Philippine Journal of Ophthalmology 2024;49(1):54-60
Objective:
This paper demonstrated the effectiveness of intrastromal injection of levofloxacin 1.5%
ophthalmic solution in the management of recalcitrant Gram-positive bacterial keratitis.
Methods:
This is a report on two cases of recalcitrant bacterial keratitis encountered at the External Diseases
and Cornea Clinic of the Department of Ophthalmology and Visual Sciences at the Philippine General Hospital.
Results:
Two middle-aged females presented with bacterial keratitis unresponsive to previous antibiotic
treatment with impending corneal perforation. The Gram stain of the corneal scraping in the first case revealed Gram-positive cocci, while the second case showed encapsulated Gram-positive bacilli and encapsulated Grampositive cocci in chains. In both cases, repeated intrastromal injections of levofloxacin 1.5% in addition to increasing the frequency of topical levofloxacin 1.5% resulted in marked improvement in visual acuity and resolution of deep stromal infiltrates and hypopyon.
Conclusion
These cases highlighted the utility of intrastromal levofloxacin 1.5% ophthalmic solution in the
management of recalcitrant Gram-positive bacterial keratitis.
Fluoroquinolones
;
Levofloxacin
2.Association between the Levofloxacin Plasma Concentration and Neurological Adverse Events in an Elderly Patient
Gaeun KANG ; Seung Hyun MIN ; Jong Keun KIM ; Kyung Wook KANG
Journal of Clinical Neurology 2019;15(4):572-574
No abstract available.
Aged
;
Humans
;
Levofloxacin
;
Plasma
3.Postoperative safety outcomes in patients undergoing routine Phacoemulsification Cataract Surgery with Intraoperative Intracameral Injection of Preservative-Free Moxifloxacin versus Levofloxacin
Franz Marie Cruz ; Harvey S. Uy ; Carlo Josemaria Rubio ; Pik Sha Chan
Philippine Journal of Ophthalmology 2022;47(1):15-22
Purpose:
This study compared the safety outcomes of two intracameral fluoroquinolone antibiotics,
moxifloxacin and levofloxacin, as prophylaxis treatment in eyes that underwent uncomplicated cataract surgery.
Methods:
This is a prospective, double-masked, randomized, interventional, single-center clinical trial. Eyes
with visually-significant cataracts underwent phacoemulsification and received preservative-free intracameral
0.5% moxifloxacin [58 eyes (M group)] or 0.5% levofloxacin [56 eyes (L group)] at the end of the surgery as
antibiotic prophylaxis. The following safety parameters were evaluated postoperatively at Day 1, Week 1 and
Month 1: central retinal thickness (CRT), macular volume (MV), central corneal thickness (CCT), and
endothelial cell density (ECD). In-between group comparison was made at each of the 4 study visits using
Student’s t-test.
Results:
Both M and L groups had similar baseline characteristics. There were no significant differences in
CRT, MV, CCT and ECD between the 2 groups at each time point in the study. There were no significant
differences in the mean changes in CRT, MV, CCT and ECD from baseline to final visit between the 2 groups.
No study-related adverse events were observed during the study period.
Conclusion
Intracameral application of preservative-free 0.5% moxifloxacin and 0.5% levofloxacin appear to
have similar safety outcomes when used as antibacterial prophylaxis among eyes undergoing cataract surgery.
Based on the results, both fluoroquinolone agents are potentially suitable options for endophthalmitis
chemoprophylaxis.
Levofloxacin
;
Moxifloxacin
;
Fluoroquinolones
4.Clinical Efficacy and Safety of Intravenous levofloxacin in Patients of Abdominal Operati.
Yoon Seok CHAE ; Sub Jin CHOI ; Jong Hoon LEE ; Kyung Sik KIM ; Woo Jung LEE ; Byong Ro KIM
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2001;5(1):169-173
BACKGROUND/AIMS: For the investigation of the efficacy and safety of intravenous levofloxacin, The clinical study was carrried out in 30 patients with abdominal operation, especially in hepatobiliary and pancreatic division. METHODS: Randomly chosen patients received intravenous levofloxacin (250mg bid) for only 7 days. Clinical and microbiological evaluation were conducted on the day of starting and finishing levofloxacin treatmeat except for the case of combined use of antibiotics. RESULTS: The most commonly isolated organism was staphylococcus aureus(33%, 3/9). The overall bacteriologic eradication rate was 67%, (6/9) with clinical success rate was 96%(29/30), There were no significant dverse effects to stop the administration of the drug. CONCLUSION: These results suggest that intravenous levofloxacin is effective and safe antibiotics in the fields management of abdominal operation especially in hepatobiliary and pancreas surgery.
Anti-Bacterial Agents
;
Humans
;
Levofloxacin*
;
Pancreas
;
Staphylococcus
5.The Efficacy of Oral Levofloxacin in the Treatment of Patient with Chronic Prostatitis.
Chang Soo OH ; Sang Hyeon CHEON ; Ro Jung PARK ; Mi Suk LEE
Infection and Chemotherapy 2005;37(2):99-103
PURPOSE: Antibiotic is widely used in the treatment of chronic prostatitis. In this study, we evaluated the clinical efficacy and safety of levofloxacin (Cravit(R)) in the treatment of patients with chronic prostatitis. MATERIALS AND METHODS: Between March 2001 and February 2003, 64 patients with chronic bacterial (NIH-category II) and nonbacterial inflammatory prostatitis (NIH-category IIIa) were enrolled in this study. Daily 400 mg of levofloxacin was administered orally for 4-18 weeks. To determine the efficacy of levofloxacin, patients were assessed with the NIH-CPSI and examined of expressed prostatic secretion (EPS) at 3 months follow-up period. RESULTS: The CPSI of 16 patients stratified into NIH-category II was 24.9+/-4.7 before and 14.1+/-6.5 after the treatment. For 48 patients stratified into NIH-category IIIa, the CPSI value before and after the treatment was 23.9+/-4.4 and 13.2+/-5.7, respectively. 40 patients (62.5%) showed mild to moderate improvement in NIH-CPSI, and 23 patients (35.9%) showed improvement in the laboratory profile according to the count of leukocytes (WBC <10/HPF) in EPS. Adverse reaction was noted in 1 patient during the treatment. Conclusions:This study shows that levofloxacin may be a safe and effective agent in treating either chronic bacterial prostatitis or chronic nonbacterial inflammatory prostatitis with few adverse reactions.
Follow-Up Studies
;
Humans
;
Leukocytes
;
Levofloxacin*
;
Prostatitis*
6.The Efficacy of Oral Levofloxacin in the Treatment of Patient with Chronic Prostatitis.
Chang Soo OH ; Sang Hyeon CHEON ; Ro Jung PARK ; Mi Suk LEE
Infection and Chemotherapy 2005;37(2):99-103
PURPOSE: Antibiotic is widely used in the treatment of chronic prostatitis. In this study, we evaluated the clinical efficacy and safety of levofloxacin (Cravit(R)) in the treatment of patients with chronic prostatitis. MATERIALS AND METHODS: Between March 2001 and February 2003, 64 patients with chronic bacterial (NIH-category II) and nonbacterial inflammatory prostatitis (NIH-category IIIa) were enrolled in this study. Daily 400 mg of levofloxacin was administered orally for 4-18 weeks. To determine the efficacy of levofloxacin, patients were assessed with the NIH-CPSI and examined of expressed prostatic secretion (EPS) at 3 months follow-up period. RESULTS: The CPSI of 16 patients stratified into NIH-category II was 24.9+/-4.7 before and 14.1+/-6.5 after the treatment. For 48 patients stratified into NIH-category IIIa, the CPSI value before and after the treatment was 23.9+/-4.4 and 13.2+/-5.7, respectively. 40 patients (62.5%) showed mild to moderate improvement in NIH-CPSI, and 23 patients (35.9%) showed improvement in the laboratory profile according to the count of leukocytes (WBC <10/HPF) in EPS. Adverse reaction was noted in 1 patient during the treatment. Conclusions:This study shows that levofloxacin may be a safe and effective agent in treating either chronic bacterial prostatitis or chronic nonbacterial inflammatory prostatitis with few adverse reactions.
Follow-Up Studies
;
Humans
;
Leukocytes
;
Levofloxacin*
;
Prostatitis*
7.Two Cases of Green Nail Syndrome.
Beom Joon KIM ; Hee Jin BYUN ; Dong Hun LEE ; Soyun CHO ; Myeung Nam KIM ; Byung In RO ; Yang Won LEE ; Yong Beom CHOE ; Kyu Joong AHN
Korean Journal of Medical Mycology 2006;11(3):163-165
Green nail syndrome is characterized by greenish discoloration of the nail. It is caused by Pseudomas aeruginosa which is an aerobic gram-negative rod found in moist environment. The most common predisposing factors are frequent exposure to water and trauma history. Herein, we report two cases of green nail syndrome who developed greenish discoloration of finger nails, which were treated by systemic levofloxacin and gentian violet application.
Causality
;
Fingers
;
Gentian Violet
;
Levofloxacin
;
Pseudomonas aeruginosa
;
Water
8.Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis.
Hua XU ; Xue-jun SHANG ; Xia CAI ; Wen-hui TENG ; Yu-feng HUANG
National Journal of Andrology 2007;13(4):338-341
OBJECTIVETo study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis.
METHODSEighty patients with Type IIIA prostatitis were equally randomized into a Longqingpian group and a Puleanpian group, both treated for 12 weeks. The former were given Longqingpian (once 6 tablets, twice a day) combined with Levofloxacin (once 0.2 g, twice a day) during the first 4 weeks, followed by Longqingpian alone (once 6 tablets, twice a day) for 8 weeks. The latter received Puleanpian (once 4 tablets, 3 times a day) combined with Levofloxacin (once 0.2 g, twice a day) in the initial 4 weeks, followed by Puleanpian alone (once 4 tablets, 3 times a day) for 8 weeks. Before and 4, 8, and 12 weeks after the treatment, all the patients were evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and EPS examination.
RESULTSAfter 4-week, 8-week and 12-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life dropped significantly in both groups compared with pre-treatment (P < 0.05 or 0.01), so did the leukocyte count in EPS (P < 0.05). Compared with the 4-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life were shown to be significantly different (P < 0.05) in the Longqingpian group from the 8-week and 12-week treatment, except the leukocyte count in EPS. However, there was no significant difference between the 8-week and 12-week treatment in any of the indexes (P > 0.05). Longqingpian effected significant differences in the above indexes (P < 0.05), while Puleanpian did not after the treatment (P > 0.05). And the lecithin Amato body analysis revealed no significant changes in EPS after the treatment in either group (P > 0.05).
CONCLUSIONLongqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients.
Adult ; Chronic Disease ; Humans ; Levofloxacin ; Male ; Middle Aged ; Ofloxacin ; therapeutic use ; Phytotherapy ; Prostatitis ; drug therapy
9.HPLC-MS identification of degradation products of levofloxacin.
Wei-Jian WANG ; Tao LI ; Jun LI ; Qi LIU ; Yuan-Chao XIE
Acta Pharmaceutica Sinica 2012;47(4):498-501
The study aims to identify the degradation products of levofloxacin by HPLC-MS. The degradation products of levofloxacin were chromatographed on Agilent Zorbax Extend-C18 column (250 mm x 4.6 mm, 5 microm). The mobile phase was 0.1% ammonium acetate solution (using methanoic acid to adjust to pH 3.5)-acetonitrile at the flow rate of 0.5 mL x min(-1) (gradient elution), the column temperature was 40 degrees C. Descarboxyl levofloxacin, desmethyl levofloxacin and levofloxacin N-oxide were identified through comparing with the standard spectrum and the results of mass spectrometry, i.e. m/z 318.2 was descarboxyl levofloxacin, m/z 348.2 was desmethyl levofloxacin, m/z 378.1 was levofloxacin-N-oxide. This method is simple, fast, accurate and suitable for the identification of degradation products of levofloxacin.
Chromatography, High Pressure Liquid
;
methods
;
Drug Stability
;
Levofloxacin
;
Mass Spectrometry
;
methods
;
Ofloxacin
;
analysis
;
chemistry
;
Photolysis
10.Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease.
Joo Hyun LIM ; Sang Gyun KIM ; Ji Hyun SONG ; Jae Jin HWANG ; Dong Ho LEE ; Jae Pil HAN ; Su Jin HONG ; Ji Hyun KIM ; Seong Woo JEON ; Gwang Ha KIM ; Ki Nam SHIM ; Woon Geon SHIN ; Tae Ho KIM ; Sun Moon KIM ; Il Kwon CHUNG ; Hyun Soo KIM ; Heung Up KIM ; Joongyub LEE ; Jae Gyu KIM
Gut and Liver 2017;11(2):226-231
BACKGROUND/AIMS: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. METHODS: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. RESULTS: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655). CONCLUSIONS: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
Amoxicillin
;
Clarithromycin
;
Compliance
;
Follow-Up Studies
;
Helicobacter pylori*
;
Helicobacter*
;
Humans
;
Levofloxacin
;
Peptic Ulcer*
;
Ulcer